<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent studies have shown that point mutations in granulocyte colony-stimulating factor receptor (G-CSFR) are involved in the pathogenesis of severe <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo> <z:chebi fb="0" ids="29425">(SCN)</z:chebi> and in the transformation of <z:chebi fb="0" ids="18022">SCN</z:chebi> to <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>It is reasonably speculated that the abnormalities in the signal transduction pathways for G-CSF could be partly responsible for the pathogenesis and the development to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, we investigated the structural and functional abnormalities of the G-CSFR in 14 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and 10 <z:mpath ids='MPATH_458'>normal</z:mpath> subjects </plain></SENT>
<SENT sid="3" pm="."><plain>In in vitro colony forming assay, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> samples showed reduced response to growth factors </plain></SENT>
<SENT sid="4" pm="."><plain>However, G-CSF, but not GM-CSF and IL-3, enhanced clonal growth in three cases of high risk patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> having progressed to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>)) and one low risk patient (RA) </plain></SENT>
<SENT sid="5" pm="."><plain>Eight out of 14 patients including above 4 patients demonstrated a common deletion of the G-CSFR cDNA; a deletion of three <z:chebi fb="9" ids="36976">nucleotides</z:chebi> (2128-2130) in the juxtamembrane domain of the G-CSFR, which resulted in a conversion of Asn(630)Arg(631) to Lys(630) </plain></SENT>
<SENT sid="6" pm="."><plain>To assess the functional activities of this deletion in the G-CSFR isoform, a mutant with the same three-nucleotide deletion was constructed by site-directed mutagenesis </plain></SENT>
<SENT sid="7" pm="."><plain>FDCP-2 cells expressing the G-CSFR isoform responded to G-CSF, and exhibited proliferative responses than did those cells having <z:mp ids='MP_0002169'>wild-type</z:mp> G-CSFR </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, these isoforms showed prolonged activation of STAT3 in response to G-CSF than did the <z:mp ids='MP_0002169'>wild-type</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggest that the deletion in the juxtamembrane domain of the G-CSFR gives a growth advantage to abnormal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> clones and may contribute to the pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>